Partnering with VaxEquity
The extent of VaxEquity’s intellectual property portfolio ensures that RNA assets can be designed and developed rapidly, whilst advances in nucleic acid technology enable rapid manufacturing at commercial scales. VaxEquity’s proprietary technology can be applied to vaccines and therapeutics, and we are interested to hear from partners with therapeutic or vaccine programs that would benefit from a license to our technology to increase delivery of proteins for research, clinical and commercial applications. VaxEquity has a portfolio of its own products and we are seeking partners who recognise the opportunities presented by our internal programs.